Galapagos (GLPG)
(Real Time Quote from BATS)
$28.42 USD
-0.21 (-0.73%)
Updated Apr 26, 2024 10:46 AM ET
2-Buy of 5 2
D Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
GLPG 28.42 -0.21(-0.73%)
Will GLPG be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for GLPG based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GLPG
Down -9.97% in 4 Weeks, Here's Why You Should You Buy the Dip in Galapagos (GLPG)
Bristol Myers (BMY) Reports Positive Colorectal Cancer Study Data
GLPG: What are Zacks experts saying now?
Zacks Private Portfolio Services
Fate Therapeutics (FATE) Surges 86.4% YTD on Pipeline Progress
Amylyx (AMLX) Withdraws ALS Drug, Cuts Workforce by 70%
After Plunging -7.94% in 4 Weeks, Here's Why the Trend Might Reverse for Galapagos (GLPG)
Other News for GLPG
Galapagos NV Unveils CAR-T Therapy Advances
Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
Galapagos announces clinical/ translational data on hematological cancer care
Crocs initiated, Bill downgraded: Wall Street's top analyst calls
Galapagos just downgraded at BofA, here's why